For citations:
Zvonkov E.E., Koroleva D.A., Gabeeva N.G., Shchekina A.E., Telyashov M.A., Aleshina O.A., Biderman B.V., Sudarikov A.B., Obukhova T.N., Galtseva I.V., Dvirnik V.N., Troitskaya V.V., Galstyan G.M., Maschan M.A., Parovichnikova E.N. Combination of ibrutinib and venetoclax followed by Chimeric Antigen Receptor T-cell therapy in the first line of treatment in an elderly patient with mantle cell lymphoma with hyperleukocytosis and mutation in the TP53 gene. Russian journal of hematology and transfusiology. 2022;67(3):441-452. (In Russ.) https://doi.org/10.35754/0234-5730-2022-67-3-441-452
Email this article 
